SEC Company Response from Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747) (SCNI) — Jun 5, 2019

Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747)
Date: June 5, 2019 · CIK: 0001611747 · Accession: 0001213900-19-010137

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-230484

Date

June 10, 2019

Author

Ron Babecoff

Form

CORRESP

Company

Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747)

Letter

Re: BiondVax Pharmaceuticals Ltd.

Division of Corporation Finance

Securities and Exchange Commission

Washington, DC 20549

Registration Statement on Form F-1/A (Registration No. 333-230484)

Ladies and Gentlemen:

Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, BiondVax Pharmaceuticals Ltd. (the “Company”) hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-1/A (the “Registration Statement”) be accelerated to, and that the Registration Statement become effective at 9:00 a.m., New York City Time on Monday June 10, 2019, or as soon thereafter as practicable.

The Company hereby acknowledges the following:

● should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

● the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

● the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,
BIONDVAX PHARMACEUTICALS LTD.

Show Raw Text

CORRESP
1
filename1.htm

Division of Corporation Finance

Securities and Exchange Commission

Washington, DC 20549

    Re:
    BiondVax Pharmaceuticals Ltd.

Registration Statement
on Form F-1/A (Registration No. 333-230484)

Ladies and Gentlemen:

Pursuant
to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, BiondVax Pharmaceuticals Ltd. (the “Company”)
hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-1/A (the “Registration Statement”)
be accelerated to, and that the Registration Statement become effective at 9:00 a.m., New York City Time on Monday June 10, 2019,
or as soon thereafter as practicable.

The
Company hereby acknowledges the following:

    ●
    should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

    ●
    the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

    ●
    the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

    Very truly yours,

    BIONDVAX PHARMACEUTICALS LTD.

    By:

        /s/ Ron Babecoff

    Name:
    Ron Babecoff

    Title:
    Chief Executive Officer and Director

SecProbe.io